UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 139

Sortiert nach

Targeted Therapy in the Management of Advanced Gastric Cancer: Are We Making Progress in the Era of Personalized Medicine?

The oncologist (Dayton, Ohio), 2012-03, Vol.17 (3), p.346-358

2012

Volltextzugriff (PDF)

Molecular targeted therapies in advanced gastric cancer: does tumor histology matter?

Therapeutic Advances in Gastroenterology, 2013-01, Vol.6 (1), p.15-31

2013

Volltextzugriff (PDF)

The Significance of Early Alpha‐Fetoprotein Level Changes in Predicting Clinical and Survival Benefits in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib

The oncologist (Dayton, Ohio), 2011-09, Vol.16 (9), p.1270-1279

2011

Volltextzugriff (PDF)

Living With “Man’s Fate” Away From Home

Journal of patient experience, 2016-12, Vol.3 (4), p.105-107

2016

Volltextzugriff (PDF)

Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy

Anti-cancer agents in medicinal chemistry, 2013-03, Vol.13 (3), p.382

2013

Volltextzugriff (PDF)

Time course and substance P effects on the vascular and morphological changes in adjuvant-induced monoarthritic rats

International immunopharmacology, 2004-02, Vol.4 (2), p.299-310

2004

Volltextzugriff (PDF)

The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?

Acta ophthalmologica (Oxford, England), 2013-11, Vol.91 (7), p.604-609

2013

Volltextzugriff (PDF)

Integrating Molecular Mechanisms and Clinical Evidence in the Management of Trastuzumab Resistant or Refractory HER‐2+ Metastatic Breast Cancer

The oncologist (Dayton, Ohio), 2011-11, Vol.16 (11), p.1535-1546

2011

Volltextzugriff (PDF)

Coloncancer in a patient with underlying aplastic anemia: A clinical challenge

World journal of clinical oncology, 2012, Vol.3 (2), p.29

Wong, Hilda

2012

Volltextzugriff (PDF)

The use of single‐agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child‐Pugh B liver cirrhosis

Cancer, 2012-11, Vol.118 (21), p.5293-5301

2012

Volltextzugriff (PDF)

Intramuscular recurrence in a hepatocellular carcinoma patient with indolent disease course

World journal of surgical oncology, 2008-04, Vol.6 (1), p.42-42, Article 42

2008

Volltextzugriff (PDF)

Is There a Role for Unstimulated Thyroglobulin Velocity in Predicting Recurrence in Papillary Thyroid Carcinoma Patients with Detectable Thyroglobulin after Radioiodine Ablation?

Annals of surgical oncology, 2012-10, Vol.19 (11), p.3479-3485

2012

Volltextzugriff (PDF)

The Emergence of a Community-based Social Assistance Programme in Urban China

Social policy & administration, 1999-03, Vol.33 (1), p.39-54

1999

Volltextzugriff (PDF)

Lobular breast cancers lack the inverse relationship between ER/PR status and cell growth rate characteristic of ductal cancers in two independent patient cohorts: implications for tumor biology and adjuvant therapy

BMC cancer, 2014-11, Vol.14 (1), p.826-826, Article 826

2014

Volltextzugriff (PDF)

Changing pattern of recurrences in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy in the era of dual anti-HER2 therapy

Postgraduate medical journal, 2019-03, Vol.95 (1121), p.155

2019

Volltextzugriff (PDF)

Use of sertraline for antihistamine-refractory uremic pruritus in renal palliative care patients

Journal of palliative medicine, 2013-08, Vol.16 (8), p.966

2013

Volltextzugriff (PDF)

Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease

Investigational new drugs, 2012-12, Vol.30 (6), p.2384-2390

2012

Volltextzugriff (PDF)

Efficacy and saftey of capecitabine, oxaliplatin, and irinotecan (xeloxiri) as salvage therapy for patients with treatment-refractory metastatic colorectal cancer: A prospective, open-label, phase II study

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.e14511-e14511

2014

Volltextzugriff (PDF)

Review: metronomic chemotherapy for advanced cutaneous angiosarcoma

Clinical advances in hematology & oncology, 2011-06, Vol.9 (6), p.504-506

2011

Volltextzugriff (PDF)

The Outcomes and Safety of Single‐Agent Sorafenib in the Treatment of Elderly Patients with Advanced Hepatocellular Carcinoma (HCC)

The oncologist (Dayton, Ohio), 2011-12, Vol.16 (12), p.1721-1728

2011

Volltextzugriff (PDF)

Comparison of Cetuximab and Bevacizumab as First-Line Treatment in KRAS Wild Type Advanced Colorectal Cancer Patients: A Retrospective Analysis

Annals of oncology, 2014-06, Vol.25, p.ii76-ii76

2014

Volltextzugriff (PDF)

Advanced Pancreatic Cancer: Flourishing Novel Approaches in the Era of Biological Therapy

The oncologist (Dayton, Ohio), 2014-09, Vol.19 (9), p.937-950

2014

Volltextzugriff (PDF)

Efficacy and tolerability of adjuvant oral capecitabine plus intravenous oxaliplatin (XELOX) in Asian patients with colorectal cancer: 4-year analysis

Asian Pacific journal of cancer prevention : APJCP, 2013-01, Vol.14 (11), p.6585-6590

2013

Volltextzugriff (PDF)

Colon cancer in a patient with underlying aplastic anemia: A clinical challenge

World journal of clinical oncology, 2012-02, Vol.3 (2), p.29-31

2012

Volltextzugriff (PDF)

A multicenter phase II study of sorafenib, capecitabine, and oxaliplatin (SECOX) in patients with advanced hepatocellular carcinoma: Final results of Hong Kong-Singapore Hepatocellular Carcinoma Research Collaborative Group study

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.4117-4117

2013

Volltextzugriff (PDF)

1 – 25 von 139

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(128)
Mit Volltextzugriff
(122)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Targeted Therapy in the Management of Advanced Gastric Cancer: Are We Making Progress in the Era of Personalized Medicine?

Molecular targeted therapies in advanced gastric cancer: does tumor histology matter?

The Significance of Early Alpha‐Fetoprotein Level Changes in Predicting Clinical and Survival Benefits in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib

Living With “Man’s Fate” Away From Home

Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy

Time course and substance P effects on the vascular and morphological changes in adjuvant-induced monoarthritic rats

The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?

Integrating Molecular Mechanisms and Clinical Evidence in the Management of Trastuzumab Resistant or Refractory HER‐2+ Metastatic Breast Cancer

Coloncancer in a patient with underlying aplastic anemia: A clinical challenge

The use of single‐agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child‐Pugh B liver cirrhosis

Intramuscular recurrence in a hepatocellular carcinoma patient with indolent disease course

Is There a Role for Unstimulated Thyroglobulin Velocity in Predicting Recurrence in Papillary Thyroid Carcinoma Patients with Detectable Thyroglobulin after Radioiodine Ablation?

The Emergence of a Community-based Social Assistance Programme in Urban China

Lobular breast cancers lack the inverse relationship between ER/PR status and cell growth rate characteristic of ductal cancers in two independent patient cohorts: implications for tumor biology and adjuvant therapy

Changing pattern of recurrences in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy in the era of dual anti-HER2 therapy

Use of sertraline for antihistamine-refractory uremic pruritus in renal palliative care patients

Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease

Efficacy and saftey of capecitabine, oxaliplatin, and irinotecan (xeloxiri) as salvage therapy for patients with treatment-refractory metastatic colorectal cancer: A prospective, open-label, phase II study

Review: metronomic chemotherapy for advanced cutaneous angiosarcoma

The Outcomes and Safety of Single‐Agent Sorafenib in the Treatment of Elderly Patients with Advanced Hepatocellular Carcinoma (HCC)

Comparison of Cetuximab and Bevacizumab as First-Line Treatment in KRAS Wild Type Advanced Colorectal Cancer Patients: A Retrospective Analysis

Advanced Pancreatic Cancer: Flourishing Novel Approaches in the Era of Biological Therapy

Efficacy and tolerability of adjuvant oral capecitabine plus intravenous oxaliplatin (XELOX) in Asian patients with colorectal cancer: 4-year analysis

Colon cancer in a patient with underlying aplastic anemia: A clinical challenge

A multicenter phase II study of sorafenib, capecitabine, and oxaliplatin (SECOX) in patients with advanced hepatocellular carcinoma: Final results of Hong Kong-Singapore Hepatocellular Carcinoma Research Collaborative Group study

Suchergebnisse filtern